Zobrazeno 1 - 10
of 25
pro vyhledávání: '"59"'
Autor:
Friedrich Kaufmann, Volkmar Falk, Felix Schoenrath, Julia Stein, C. Knosalla, T. Haese, Johanna Mulzer, H. Krastev, Evgenij Potapov, Jan Knierim, Christoph Hoermandinger, M. Müller
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S340
Purpose 6-minute walk distance (6MWD) is a predictor of outcome in patients with left ventricular assist device (LVAD). The aim of this study was to evaluate the exercise capacity and LVAD-flow parameters in relation to right ventricular function. Me
Publikováno v:
The Journal of Heart and Lung Transplantation. 23:461-465
Background We compared the use of intravenous ganciclovir and cytomegalovirus hyperimmune globulin (CMVIG) as a pre-emptive treatment for cytomegalovirus (CMV)-positive heart transplant recipients. Methods Of 59 CMV-seropositive adult heart transplan
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S202-S203
Purpose The combination of isosorbide dinitrate/hydralazine (ISDN/HYD) offers direct arterial and venous vasodilation without adversely affecting renal function. It is used as an adjunct to standard heart failure therapies in adults with reduced ejec
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S376
Purpose Calcineurin inhibitor (CNI) or mammalian target of rapamycin inhibitor (mTORi) maintenance immunosuppression (MI) may lead to complications that require interim alternative therapies. The goal of this study was to evaluate the safety and effi
Autor:
François Parquin, L. Beaumont, S. Colin de Verdière, Anne-Françoise Roux, O. Brugière, A. Hamid, S. De Miranda, C. Roy, Clément Picard, Eric Farfour
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S340
Purpose Management of neutropenia, the main side effect of Valganciclovir, may affect final transplant results. The main objective of this study is to evaluate the safety of Valganciclovir in D+/R- patients. The secondary objectives are to assess the
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S525
Introduction Cardiobacterium valvarum is a HACEK organism known for causing infective endocarditis (IE); there are no reported cases implicating this bacterium in left ventricular assist device (LVAD) infections in the English literature. Case Report
Autor:
Shashank Sharma, Francis D. Pagani, Shannon M. Dunlay, Nicholas A. Haglund, Keith D. Aaronson, Jennifer A Cowger, Mary Beth Davis, Simon Maltais, Palak Shah, John M. Stulak, Faraz Masood
Publikováno v:
The Journal of Heart and Lung Transplantation. 34:1535-1541
Background Pump thrombosis is a major adverse event in patients supported with a left ventricular assist device (LVAD). Treatment approaches include device exchange, lytic therapy, or augmentation of anticoagulation or antiplatelet therapy. The optim
Autor:
Raymond L. Benza, B. Brockmann, Sylvia Nikkho, Harrison W. Farber, Paul A. Corris, Adaani E. Frost, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Christian Meier
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S18
Purpose The REVEAL risk score (RRS) predicts 1-year survival in patients with pulmonary arterial hypertension; it also improved with riociguat in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) i
Autor:
Pavan Atluri, Kimberly Urgo, Joyce Wald, Michael V. Genuardi, Thomas C. Hanff, Monique S. Tanna, Jeremy A. Mazurek, Edo Y. Birati, Robert S Zhang, Carli J. Peters, Christopher M. Domenico
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S447
Purpose Intravenous iron repletion in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency has been shown to safely improve functional capacity and quality of life. Despite common use of intravenous (IV) iron repleti
Publikováno v:
The Journal of Heart and Lung Transplantation. 39:S323
Purpose Antibody induction therapy has been shown to reduce acute rejection episodes in organ transplantation. Universal basiliximab (BAS) induction therapy was discontinued at our center due to lack of efficacy versus no induction. Targeted inductio